A molecular test called PancreaSeq accurately classifies pancreatic cysts as potentially cancerous or benign, according to a large, multi-center study led by University of Pittsburgh School of Medicine and UPMC researchers.
A molecular test called PancreaSeq accurately classifies pancreatic cysts as potentially cancerous or benign, according to a large, multi-center study led by University of Pittsburgh School of Medicine and UPMC researchers.
PancreaSeq is a product of the Molecular & Genomic Pathology Laboratory at the University of Pittsburgh Medical Center.